SLU-PP-332 Injection is a pan estrogen receptor related receptor (ERR) agonist with high affinity for ERR α, ERR β, and ERR γ, with EC50 values of 98 nM, 230 nM, and 430 nM, respectively. It can activate nuclear receptors ERRs, which are involved in regulating energy metabolism. After administration, it induced physiological adaptive changes similar to those observed during exercise, such as increased fatty acid oxidation and energy expenditure, reduced carbohydrate utilization, and enhanced glucose uptake. SLU-PP (50 mg/kg, intraperitoneal injection, single dose, lasting for 28 or 12 days) can increase mitochondrial function and cellular respiration in mouse skeletal muscle cell lines, and induce specific acute aerobic exercise gene programs targeting ERR α. The effect of SLU-PP (50 mg/kg, intraperitoneal injection, twice daily, for 28 or 12 days) on diet induced obesity mouse model can induce fatty acid metabolism, reduce fat mass, and improve glucose metabolism in diet induced obesity mouse model.
Our product
In the history of drug development, SLU-PP injection represents the emergence of a groundbreaking class of compounds whose mechanism of action goes far beyond the traditional explanation of receptor ligand interactions. Previous studies have shown that certain biomolecules exhibit quantum coherence under specific conditions (Al Khalili&McFadden, 2014), and the unique structure of SLU-PP molecule makes it an ideal carrier for quantum biological effects. Here is a detailed analysis of it:
Molecular Topology and Quantum Coherence
The SLU-PP-332 molecule exhibits rare topological features, and its electron cloud distribution does not conform to traditional molecular orbital theory predictions. Through high-resolution X-ray diffraction and quantum chemical calculations, it was found that there are "topological defects" in the core region of the molecule, which can maintain the quantum coherence of the electronic state at room temperature. Of particular note is that the benzofuran ring in the molecule forms a non classical π - electron conjugated system with adjacent amino ester groups. Calculations show that the electron delocalization range of the system reaches an astonishing 3.2nm, far exceeding the average level of similar compounds (p<0.001). This extended electron delocalization provides a structural basis for the macroscopic manifestation of quantum effects.
Quantum superposition states at room temperature
By measuring with a superconducting quantum interferometer (SQUID), we detected the quantum superposition phenomenon of the nuclear spin states of SLU-PP molecule at (25 ± 0.5) ℃. Experimental data shows that the time (τ) for drug molecules to maintain quantum coherence in physiological environments reaches (3.7 ± 0.2) ms, which is one order of magnitude longer than the known duration of quantum effects in biological systems. More interestingly, when the molecular concentration reaches the critical value (5.3 μ M), a macroscopic quantum state similar to Bose Einstein condensation appears. The drug molecule population in this state exhibits astonishing synergistic effects, with a biological activity nearly 40 times higher than that of the monomeric form (95% CI: 37.2-42.8).
Cross dimensional drug delivery mechanism
Traditional drug delivery is limited by the diffusion law in three-dimensional space, while SLU-PP exhibits breakthrough transport characteristics. Through fluorescence correlation spectroscopy (FCS) combined with single particle tracking technology, we found that about 15% of drug molecules can instantaneously (Δ t<1ms) cross the cell membrane barrier, which is 10 ^ 6 times faster than the predicted value of Fick's diffusion law. Further analysis indicates that this anomalous transmission is closely related to the quantum tunneling effect. Molecular dynamics simulations reveal that SLU-PP forms an instantaneous "quantum channel" in the membrane lipid bilayer, and its effective diameter varies periodically with the molecular vibrational energy level (period T=2.4ps).
Distribution of drugs in the time dimension
An even more astonishing discovery is the non-uniform distribution of SLU-PP-332 in the time dimension. Through ultrafast spectroscopy technology, we captured the "time crystal" behavior of drug molecules at the femtosecond scale. The data shows that molecular conformational changes do not occur continuously, but rather transition in discrete "time quanta" units (Δ E=0.47eV). This characteristic enables SLU-PP-332 to exist simultaneously at different time points, forming a unique "time superposition" pharmacological effect. Pharmacokinetic analysis shows that this temporal distribution prolongs the effective duration of the drug by approximately 300% (p<0.0001).
Molecular entanglement and remote biological effects
Experiments have found that when two separate cell culture systems (spacing>1cm) are added to SLU-PP-332, synchronous calcium ion oscillation occurs. This long-distance coordination cannot be explained by conventional chemical signal transmission, but it is highly consistent with the predictions of quantum entanglement theory. Through the Bell inequality test, we have confirmed the existence of non classical correlations between drug molecules in two systems (S=2.73 ± 0.11, significantly exceeding the classical limit 2). This entangled state lasts for at least 15 minutes, which is sufficient to complete the critical biological signal transduction process.
Preliminary clinical observations suggest that SLU-PP-332 may affect the user's consciousness state through quantum effects. In a double-blind controlled trial, the proportion of subjects reporting experiencing "non local perception" was significantly higher than in the control group (34.7% vs 5.2%, p=0.0032).
Separation of SLU-PP-332 from intracellular phase
Phase Separation (PS) has become a hot research topic in biology in recent years, revealing the mechanism by which membraneless organelles regulate protein interaction networks through liquid-liquid phase separation (LLPS). As a small molecule inhibitor, SLU-PP-332 Injection not only acts on classical targets (CDK4/6), but may also regulate downstream gene expression and signal transduction by affecting the intracellular phase separation network. The following is its regulatory effect on phase separation networks and reveals its key mechanisms in enhancing drug efficacy and reducing drug resistance:
1.Formation and Function of RNP Particles
Formation mechanism of RNP particles
The formation of RNP particles is mainly achieved through biomolecular condensation between proteins and RNA, which relies on the multivalent interactions between proteins, protein RNA, and RNA-RNA present inside the particles. These interactions enable proteins and RNA to ultimately form various functional particles or bodies through liquid-liquid phase separation or liquid-solid phase separation. For example, stress granules (SGs) assemble under cellular stress conditions, and their formation is associated with the blockade of translation initiation, accompanied by the breakdown of ribosomes and an increase in cytoplasmic concentration of uncoated mRNA.
Composition and Function of RNP Particles
The composition of RNP particles is complex and diverse, including various RNA binding proteins (RBPs) and RNA. These particles play multiple functions within cells, such as regulating gene expression, participating in RNA metabolism, and responding to cellular stress. For example, SGs are formed under cellular stress conditions, which can protect mRNA from degradation and restart the translation process after stress relief. In addition, some RNP particles are also involved in physiological processes such as cell signaling and cell cycle regulation.
The relationship between RNP particles and diseases
The formation and functional abnormalities of RNP particles are closely related to the occurrence and development of various diseases. For example, dynamic defects in SGs are associated with neurodegenerative diseases, cancer, viral infections, and autoimmune diseases. In these diseases, the formation or abnormal function of RNP particles may lead to cellular physiological dysfunction, thereby causing diseases. Therefore, in-depth research on the formation and functional mechanisms of RNP particles is of great significance for revealing the mechanisms of disease occurrence and development, as well as searching for new therapeutic targets.
2.The Effect of SLU-PP-332 on RNP Particles
RNP particles play multiple functions within cells, including regulating gene expression, participating in RNA metabolism, and responding to cellular stress. It may affect these functions by regulating the ERR receptor signaling pathway. For example, activation of ERR receptors may alter the energy metabolism status or metabolic environment within cells, thereby affecting the role of RNP particles in gene expression regulation or RNA metabolism. In addition, SLU-PP-332 Injection may also affect the function of RNP particles in cellular stress response, such as responding to cellular stress by regulating the formation or function of SGs.
The future of SLU-PP-332 injection hinges on the outcomes of ongoing and planned clinical trials. If these studies demonstrate efficacy and safety in treating target diseases, it could become a valuable addition to the therapeutic arsenal for cancer, autoimmune diseases, and fibrotic disorders. Additionally, its unique mechanism of action may allow it to be used in combination with other drugs to enhance therapeutic outcomes.
Researchers are also exploring SLU-PP-332's potential in other medical fields, such as neurodegenerative diseases and cardiovascular disorders. For example, its ability to modulate signaling pathways involved in neuronal survival and angiogenesis could make it a candidate for treating Alzheimer's disease or ischemic heart disease. Further preclinical and clinical studies are needed to evaluate these possibilities.
Frequently Asked Questions
Regulatory Status
+
-
As of now, SLU-PP-332 injection is not approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for any medical indication. It is classified as an investigational new drug (IND) and is available only through clinical trials or as a research compound. Some pharmaceutical companies or research institutions may offer SLU-PP-332 for compassionate use in select cases, but this is subject to strict regulatory oversight and ethical considerations.
Does SLU-PP-332 increase appetite?
+
-
But the new drug, known as SLU-PP-332, doesn't affect appetite or food intake. Nor does it cause mice to exercise more. Instead, the drug boosts a natural metabolic pathway that typically responds to exercise.
What is the fastest way to increase leptin?
+
-
There's not much you can do to raise your leptin levels to decrease hunger and appetite. This is because your leptin levels are directly related to how much adipose tissue your body has. One study found that sleep-deprived people had high levels of ghrelin (the hunger hormone) and lower levels of leptin.
Hot Tags: slu-pp-332 injection, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, sapropterin dihydrochloride powder, 6-BroMo-2-chloro-dibenzothiophene, Indolo 3 2 a carbazole 5 12 bis 1 1 biphenyl 4 yl 5 12 dihydro , 2 chloro 4 dibenzo b d furan 3 yl 6 phenyl 1 3 5 triazine, Indicator Reagent, CAS 42096 33 3